AstraZeneca delivered another 661,100 doses of COVID-19 Vaccine AstraZeneca to the Philippines in October, reaching the More than 10 million dose milestone in support the country’s mass vaccination program.
AstraZeneca, in partnership with the national government, local government, and the private sector is on track to deliver millions more doses between now and early next year directly and through the COVAX facility.
Lotis Ramin, added: “Reaching the milestone of 10 million doses is a significant moment for the national mass vaccination program and has made a critical difference against the pandemic. Our collaboration with the government and private sector – which we define and practice as ‘bayanihan’ – is essential to our ongoing efforts to vaccinate people as quickly as possible during this pandemic.”
Joey Concepcion, presidential adviser for entrepreneurship and Go Negosyo founder shared: “This is a milestone as we now have received a total of 10 million AstraZeneca doses in the country, and a significant portion was allocated for the inoculation of our workers, which is part of the private sector’s commitment and contribution to the national government’s fight against COVID-19. The arrival of this latest batch will help ramp up the vaccination rollout among our workers as part of our effort to protect their ranks from the dreaded Delta variant. Having all of our workers vaccinated against COVID-19 will also contribute to the safe reopening of our economy that we are all hoping for in the last quarter of the year.
Secretary Carlito Galvez, Chief Implementer of the National Task Force against COVID19, said: “As we battle the devastating impact of the Delta variant, 10 million AstraZeneca vaccine doses is a significant milestone. A continuous increase of our vaccination rates is what’s needed to get ahead of the virus, and we are thankful to our vaccine supply partners for supporting our mass vaccination objectives.”
Since the first deliveries in early 2021, the vaccine has helped prevent hundreds of thousands of hospitalizations and helped save tens of thousands of lives.
In clinical trials, COVID-19 Vaccine AstraZeneca demonstrated 100% efficacy against severe disease and hospitalization after two doses,2 and real-world evidence shows the vaccine is around 80 – 90% effective against severe disease due to WHO-identified variants of concern.
News Release
COVID-19 Vaccine AstraZeneca has been shown to be generally well tolerated. Incidents of thrombosis with thrombocytopenia (TTS), an extremely rare blood disorder, have been reported in a small number of people who received the vaccine within 14 days of the first dose which reduced to rates expected in the general population after the second dose.
To date, more than 1.3 billion doses of AstraZeneca’s vaccine have been released for supply to over 170 countries globally, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries.
More than 145 million doses of COVID-19 Vaccine AstraZeneca have been delivered through the COVAX Facility. AstraZeneca was the first global pharmaceutical company to join COVAX in June 2020 and continues to supply its COVID-19 vaccine globally at no profit during the pandemic period via COVAX, complemented by direct deliveries to governments.
COVID-19 Vaccine AstraZeneca
The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
